We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
Read MoreHide Full Article
Key Takeaways
GMED Q1 2026 worldwide net sales rose 27%, while base business sales increased 13.2%.
GMED posted a third straight quarter of 10% U.S. Spine growth; International Spine grew 16.4%.
GMED trauma revenues climbed 30.4%, driven by core trauma adoption and the Precice portfolio.
According to a report by Market Research Intellect, the musculoskeletal system market was valued at $15.6 billion in 2025 and is projected to witness a CAGR of 11.96% from 2026 to 2033, reaching an estimated $38.52 billion by 2033. This creates a favorable setup for Globus Medical’s (GMED - Free Report) broad implant portfolio across spine and orthopedics.
In the first quarter of 2026, worldwide net sales rose 27% year over year, while base business sales, excluding Nevro, increased 13.2%.
U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating. International Spine grew 16.4% as reported in the first quarter.
Trauma revenues increased 30.4% in the quarter, aided by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations, prompting the company to ship additional sets to the field in the second quarter.
Peer Update
Zimmer Biomet (ZBH - Free Report) continues to see stable demand across the global musculoskeletal market, supported by procedure volumes and ongoing new product adoption. While pricing remains a key swing factor, the first-quarter 2026 performance suggests end markets have remained resilient.
In the first quarter, large joints sales remained positive. Hips net sales were up 3.2% organically and total Knees net sales increased 1.8% organically. International net sales grew 4.2% at constant currency and 2.5% organically, reflecting healthy demand trends despite varying performance across countries.
Stryker’s (SYK - Free Report) long-term growth potential is underpinned by a vast and expanding total addressable market across its Orthopaedics business. Mako remains central to Stryker’s orthopaedics strategy and supports recurring pull-through from implants, consumables, and service.
In the first quarter of 2026, the company reported a record first-quarter performance for Mako installations in both the United States and international markets, supported by high and rising utilization rates. Management also highlighted positive surgeon feedback for Mako Shoulder and expects a full launch of Mako 4 in mid-2026. The launch is anticipated to broaden the range of procedures performed on the platform and further support utilization growth.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 33.5%, outperforming the industry’s 6.0% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.30X compared with the industry median of 4.76X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
View the Zacks #1 Rank List
Image: Bigstock
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
Key Takeaways
According to a report by Market Research Intellect, the musculoskeletal system market was valued at $15.6 billion in 2025 and is projected to witness a CAGR of 11.96% from 2026 to 2033, reaching an estimated $38.52 billion by 2033. This creates a favorable setup for Globus Medical’s (GMED - Free Report) broad implant portfolio across spine and orthopedics.
In the first quarter of 2026, worldwide net sales rose 27% year over year, while base business sales, excluding Nevro, increased 13.2%.
U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating. International Spine grew 16.4% as reported in the first quarter.
Trauma revenues increased 30.4% in the quarter, aided by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations, prompting the company to ship additional sets to the field in the second quarter.
Peer Update
Zimmer Biomet (ZBH - Free Report) continues to see stable demand across the global musculoskeletal market, supported by procedure volumes and ongoing new product adoption. While pricing remains a key swing factor, the first-quarter 2026 performance suggests end markets have remained resilient.
In the first quarter, large joints sales remained positive. Hips net sales were up 3.2% organically and total Knees net sales increased 1.8% organically. International net sales grew 4.2% at constant currency and 2.5% organically, reflecting healthy demand trends despite varying performance across countries.
Stryker’s (SYK - Free Report) long-term growth potential is underpinned by a vast and expanding total addressable market across its Orthopaedics business. Mako remains central to Stryker’s orthopaedics strategy and supports recurring pull-through from implants, consumables, and service.
In the first quarter of 2026, the company reported a record first-quarter performance for Mako installations in both the United States and international markets, supported by high and rising utilization rates. Management also highlighted positive surgeon feedback for Mako Shoulder and expects a full launch of Mako 4 in mid-2026. The launch is anticipated to broaden the range of procedures performed on the platform and further support utilization growth.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 33.5%, outperforming the industry’s 6.0% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.30X compared with the industry median of 4.76X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.